In a nation where public health policy has long been shaped by both scientific consensus and political will, the Trump administration has opened a formal review of the childhood vaccine schedule — one of the most extensive in the developed world. The question being asked is ancient in its form: how much protection is enough, and who decides? The pharmaceutical industry, standing on decades of immunological research, warns that any retreat from the current standard risks trading hard-won safety for an illusion of simplicity.
US vaccine review sparks industry pushback over protection standards
Potential reduction in vaccine protection could increase risk of serious and life-threatening diseases in US children if policy changes are implemented.